| Code | 9876E | ||||||||||
| MA number | 44/0179/25-S | ||||||||||
| Product Form: | tbl flm 60 (2x30x1)x400 mg (blis.PVC/PE/PVDC/Al)-jednotk.bal.-multibal. | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Mutual recognition procedure | ||||||||||
| MAH, country: | Sandoz Pharmaceuticals d.d., Slovenia | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 16.05.2025 |
| Validity: | 16.05.2030 |
| Pediatric posology: | Yes |
| Pediatric warnings: | Yes |
| SPC: |
SPC_Pazopanib Sandoz 200 mg, 400 mg_tbl flm_05/2025_REG.pdf
|
| PIL: |
PIL_Pazopanib Sandoz 200 mg, 400 mg_tbl flm_05/2025_REG.pdf
|
| Safety feature | Yes |
| Data update: | 20.05.2025 |
